Drugs / MK-1484
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05382325 | Jun 2022 → Jul 2026 overdue | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1484 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05382325 ↗ |